NASDAQ
PEPG

PepGen Ltd

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

PepGen Ltd Stock Price

Vitals

Today's Low:
$6.06
Today's High:
$6.4
Open Price:
$6.06
52W Low:
$4.32
52W High:
$20
Prev. Close:
$6.14
Volume:
38627

Company Statistics

Market Cap.:
$153.84 million
Book Value:
6.185
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-22.99%
Return on Equity TTM:
-38.82%

Company Profile

PepGen Ltd had its IPO on 2022-05-06 under the ticker symbol PEPG.

The company operates in the Healthcare sector and Biotechnology industry. PepGen Ltd has a staff strength of 54 employees.

Stock update

Shares of PepGen Ltd opened at $6.06 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.06 - $6.4, and closed at $6.33.

This is a +3.09% increase from the previous day's closing price.

A total volume of 38,627 shares were traded at the close of the day’s session.

In the last one week, shares of PepGen Ltd have slipped by -2.01%.

PepGen Ltd's Key Ratios

PepGen Ltd has a market cap of $153.84 million, indicating a price to book ratio of 1.6645 and a price to sales ratio of 0.

In the last 12-months PepGen Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-75173000. The EBITDA ratio measures PepGen Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, PepGen Ltd’s operating margin was 0% while its return on assets stood at -22.99% with a return of equity of -38.82%.

In Q2, PepGen Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

PepGen Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.27 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PepGen Ltd’s profitability.

PepGen Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.1653. Its price to sales ratio in the trailing 12-months stood at 0.

PepGen Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$182.09 million
Total Liabilities
$16.94 million
Operating Cash Flow
$0
Capital Expenditure
$1.01 million
Dividend Payout Ratio
0%

PepGen Ltd ended 2024 with $182.09 million in total assets and $0 in total liabilities. Its intangible assets were valued at $182.09 million while shareholder equity stood at $147.28 million.

PepGen Ltd ended 2024 with $0 in deferred long-term liabilities, $16.94 million in other current liabilities, 2000.00 in common stock, $-138697000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $147.03 million and cash and short-term investments were $147.03 million. The company’s total short-term debt was $3,492,000 while long-term debt stood at $0.

PepGen Ltd’s total current assets stands at $150.38 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.82 million and inventory worth $0.

In 2024, PepGen Ltd's operating cash flow was $0 while its capital expenditure stood at $1.01 million.

Comparatively, PepGen Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$6.33
52-Week High
$20
52-Week Low
$4.32
Analyst Target Price
$23.2

PepGen Ltd stock is currently trading at $6.33 per share. It touched a 52-week high of $20 and a 52-week low of $20. Analysts tracking the stock have a 12-month average target price of $23.2.

Its 50-day moving average was $6.63 and 200-day moving average was $12.43 The short ratio stood at 3.63 indicating a short percent outstanding of 0%.

Around 6% of the company’s stock are held by insiders while 9776.1% are held by institutions.

Frequently Asked Questions About PepGen Ltd

The stock symbol (also called stock or share ticker) of PepGen Ltd is PEPG

The IPO of PepGen Ltd took place on 2022-05-06

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$1730.85
-22
-1.26%
$14.65
-0.05
-0.34%
$0.24
0
+1.28%
$52.55
0.95
+1.83%
$2.89
-0.04
-1.37%
$85.31
-5.52
-6.08%
$5.63
-0.16
-2.76%
$96.7
-0.77
-0.79%
$7.5
0.02
+0.33%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston, Massachusetts.

Address

245 Main Street, Cambridge, MA, United States, 02142